Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood DNA methylation profiles from first episode psychosis patients and controls I

ABSTRACT: Genome-wide patterns of DNA methylation were quantified using the Illumina Infinium HumanMethylationEPIC BeadChip (“EPIC array”) in DNA samples isolated from blood for schizophrenia cases, first episode psychosis patients and controls. These samples were profiled as part of a wider study where they were meta-analysed with other cohorts.

ORGANISM(S): Homo sapiens

PROVIDER: GSE152026 | GEO | 2021/04/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

Project description:Genome-wide patterns of DNA methylation were quantified using the Illumina Infinium HumanMethylation450K BeadChip (“450K array”) in DNA samples isolated from blood for schizophrenia cases, first episode psychosis patients and controls. These samples were profiled as part of a wider study where they were meta-analysed with other cohorts.

2021-04-07 | GSE152027 | GEO

Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

Project description:Blood DNA methylation profiles from schizophrenia cases, first episode psychosis patients and controls II

| PRJNA638127 | ENA

Plasma exosomes lncRNA-miRNA-mRNA network construction and its diagnostic efficacy identification in first-episode schizophrenia

Project description:This study examined the miRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the lncRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia. This study examined the mRNA expression level in exosomal derived from the plasma of first episode schizophrenia (FOS) patients and Healthy controls (HC), and explored the the potential of exosomes as biomarkers for schizophrenia.

2023-08-30 | GSE228881 | GEO

Blood DNA methylation profiles from first episode psychosis patients and controls I

Project description:Blood DNA methylation profiles from first episode psychosis patients and controls I

| PRJNA638128 | ENA

Expression data from cohort of remitted first-episode schizophrenia patients with less than 5 years of evolution

Project description:To explore the genomic architecture of schizophrenia symptomatology, we analysed blood co-expression modules, i.e. clusters of genes with highly correlated expression, in a cohort of remitted first-episode schizophrenia patients with less than 5 years of evolution, and their association with clinical data, including global functioning, clinical symptomatology and premorbid adjustment.

2022-01-18 | GSE193818 | GEO

Global and targeted metabolomics characterizes antipsychotic medications, amino acid signatures, and platelet-activating factor involvement in first-episode psychosis

Project description:We performed global untargeted metabolomics by LCMS using a Q Exactive Focus mass spectrometer coupled to a Dionex U3000 UHPLC of plasma extract from patients following First Episode Psychosis. Both positive and negative reversed phase injections were performed in triplicate with replicates performed in separate batches. The Biocrates p400 kit was also used to obtain absolute quantification of 400+ metabolites using the vendor kit, column, and data processing tools as provided. The resulting global data was processed with Compound Discoverer 2.1. The resulting output is included within this upload as well as the output from the Biocrates data processing software. Data was integrated using a variety of R scripts as detailed in the associated manuscript.

2021-11-12 | MSV000088371 | MassIVE

Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

Project description:We have previously demonstrated functional and molecular changes in hippocampal subfields in individuals with schizophrenia (SZ) psychosis associated with hippocampal excitability. In this study, we use RNA-seq and assess global transcriptome changes in the hippocampal subfields, DG, CA3, and CA1 from individuals with SZ psychosis and controls to elucidate subfield-relevant molecular changes. We also examine changes in gene expression due to antipsychotic medication in the hippocampal subfields from our SZ ON- and OFF-antipsychotic medication cohort. We identify unique subfield-specific molecular profiles in schizophrenia postmortem samples compared to controls, implicating astrocytes in DG, immune mechanisms in CA3, and synaptic scaling in CA1. We show a unique pattern of subfield-specific effects by antipsychotic medication on gene expression levels with scant overlap of genes differentially expressed by SZ disease effect versus medication effect. These hippocampal subfield changes could provide the basis for previously observed hippocampal SZ pathology and explain the lack of full efficacy of conventional antipsychotic medication on SZ symptomatology. With further characterization, the identified distinct molecular profiles of the DG, CA3, and CA1 in SZ psychosis may serve to identify potential hippocampal-based therapeutic targets.

2020-05-11 | GSE138082 | GEO

Diurnal alterations in gene expression across striatal subregions in psychosis

Project description:Background: Psychosis is a defining feature of schizophrenia and highly prevalent in bipolar disorder. Notably, individuals suffering with these illnesses also have major disruptions in sleep and circadian rhythms, and disturbances to sleep and circadian rhythms can precipitate or exacerbate psychotic symptoms. Psychosis is associated with the striatum, though no study to date has directly measured molecular rhythms and determined how they are altered in the striatum of subjects with psychosis. Methods: Here, we perform RNA-sequencing and both differential expression and rhythmicity analyses to investigate diurnal alterations in gene expression in human postmortem striatal subregions (NAc, caudate, and putamen) in subjects with psychosis relative to unaffected comparison subjects. Results: Across regions, we find differential expression of immune-related transcripts and a substantial loss of rhythmicity in core circadian clock genes in subjects with psychosis. In the nucleus accumbens (NAc), mitochondrial-related transcripts have decreased expression in psychosis subjects, but only in those who died at night. Additionally, we find a loss of rhythmicity in small nucleolar RNAs and a gain of rhythmicity in glutamatergic signaling in the NAc of psychosis subjects. Between region comparisons indicate that rhythmicity in the caudate and putamen is far more similar in subjects with psychosis than in matched comparison subjects. Conclusions: Together, these findings reveal differential and rhythmic gene expression differences across the striatum that may contribute to striatal dysfunction and psychosis in psychotic disorders.

2022-08-31 | GSE202537 | GEO

Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

Project description:Hippocampal Subfield Transcriptome Analysis in Schizophrenia Psychosis

| PRJNA574470 | ENA

Neuropsychiatric Genetics of African Populations - Psychosis (NeuroGAP-Psychosis)

Project description:Neuropsychiatric Genetics of African Populations - Psychosis (NeuroGAP-Psychosis)

| PRJNA750533 | ENA